Inspire Q2 revenue $195.9M (+30% YoY), EPS $0.32; raises FY guide, authorizes $150M buyback

Inspire Medical Systems, Inc.

2024-Q2 EPS reported -$0.01 revenue$359,895,000

Q2 revenue $195.9M (30% YoY), net income $9.8M vs loss $12.0M; diluted EPS $0.32 vs ($0.41).
FY 2024 revenue guidance raised to $788-798M (26-28% growth); EPS guidance raised to $0.60-0.80 from $0.10-0.20.
Board authorized $150M share repurchase program, first in company history, expiring August 5, 2026.
Received FDA approval for Inspire V neurostimulation system and EU MDR CE Mark for full-body MRI compatibility.
Activated 81 new U.S. centers in Q2 (total 1,316) and added 12 sales territories (total 310).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.